Having trouble accessing articles? Reset your cache.

FDA, FTC vow to crack down on advertising and commercial practices that impede biosimilar uptake

FDA and FTC Monday said they will crack down on false and misleading advertising that denigrate biosimilars and will act to prevent commercial practices that delay or block biosimilar competition.

FTC said it will “review patent settlement agreements

Read the full 382 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers